Today
-1.04%
5 Days
+0.22%
1 Month
+12.37%
6 Months
+51.55%
Year to Date
+7.28%
1 Year
+10.75%
• Johnson and Johnson shares advanced following positive clinical trial data in electrophysiology. • Management raised full-year sales and adjusted earnings guidance amid solid third-quarter performance. • Institutional capital rotated into the healthcare leader, supported by strong dividend history.
• Analysts raised Eli Lilly targets ahead of third-quarter earnings. • Strong demand for Mounjaro and Zepbound drove momentum. • Capital investments expanded manufacturing facilities globally.


| Shareholders | Proportion |
|---|---|
| BlackRock Institutional Trust Company, N.A. | 9.24% |
| MFS Investment Management | 7.79% |
| T. Rowe Price International Ltd | 3.88% |
| The Vanguard Group, Inc. | 3.16% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 39.68% |
| Investment Advisor/Hedge Fund | 28.36% |
| Research Firm | 4.94% |
| Hedge Fund | 2.46% |
Related Instruments